Vanguard National Trust
BEAM icon

Vanguard National Trust’s Beam Therapeutics BEAM Stock Holding History

Vanguard National Trust’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$786 – 790
2026
Q1 		$786 Buy
+33
New +$916 ﹤0.01% 725

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard National Trust's BEAM Position: Q2 2026 in Review

Vanguard National Trust sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 33 shares — an estimated $786 sold.

Vanguard National Trust first reported a position in BEAM in Q1 2026 and held it in 1 quarter. The position peaked at $786 in Q1 2026. 274 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Vanguard National Trust reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard National Trust sold 33 Beam Therapeutics shares in Q2 2026, an estimated $786.
  • Vanguard National Trust first reported a position in Beam Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard National Trust's Beam Therapeutics position peaked at $786 in Q1 2026.
  • 274 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.